

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

## ORIGINAL ARTICLE

# SARS-CoV-2 vaccine and increased myocarditis mortality risk:

## A population based comparative study in Japan

### AUTHORS

Sintaroo Watanabe, MD, PhD <sup>1</sup>

Rokuro Hama, MD <sup>2</sup>

### AUTHOR AFFILIAIONS

<sup>1</sup>Japan Marine United Corporation, Kure Shipyard, Kure, Japan

<https://orcid.org/0000-0002-6189-7654>

<sup>2</sup>Non-profit Organization “Japan Institute of Pharmacovigilance (Med Check)”, Osaka, Japan

<https://orcid.org/0000-0002-3802-6754>

### Correspondence to: Rokuro Hama,

Non-profit Organization “Japan Institute of Pharmacovigilance (Med Check)”,

Email: [gec00724@nifty.com](mailto:gec00724@nifty.com)

### KEYWORDS

Epidemiology, COVID-19, Drug-related side effects and adverse reactions

### WORD COUNT

Abstract: 294 words

Main: 4 713 words

Tables and Figures: 4 + 2

Supplementary Tables and Figures: 6 + 3

References: 60

**CONTRIBUTIONS:** SW proposed to conduct the study, RH and SW designed the study. Both authors independently converted the pdf data disclosed by the Japanese government into excel files and confirmed data matched. Then data collection, classification, and analyses were done first by the SW and later confirmed by RH, with any discrepancies being discussed and decided by both parties. SW and RH contributed equally to this study and reviewed the final manuscript.

**COMPETING INTERESTS:** All authors have completed the ICMJE uniform disclose form available at <https://www.icmje.org/disclosure-of-interest/>, RH wrote a book entitled “Drugs to avoid,

1 and infectious diseases including COVID-19” published on 1 December 2020.

2

3 **FUNDING**

4 This survey does not receive any financial support from businesses or public institutions.

5

6 **ETHICAL APPROVAL**

7 This study was conducted based only on data disclosed by the Japanese government. Japanese law  
8 and guidelines do not require an ethical approval for such research.

9

10 **DISCLAIMER**

11 The content is the personal view of the author and is not related to the official view of the authors'  
12 organization.

13

1 **SUMMARY BOXES**

2

3 **ALREADY KNOWN ON THIS TOPIC**

4 There are many epidemiological studies showing increased myocarditis incidence after  
5 SARS-CoV-2 vaccination. There are also some case reports of fulminant myocarditis after receiving  
6 SARS-CoV-2 vaccine. However, no epidemiological studies focusing the association between  
7 vaccination and myocarditis death.

8

9 **WHAT THIS STUDY ADDS**

10 Myocarditis mortality rate ratios (MMRRs) and their 95% confidence intervals (95% CIs) after  
11 receiving SARS-CoV-2 vaccine compared with that in the reference population (previous 3 years)  
12 were higher not only in young adults (highest in the 30s with MMRR of 7.80) but also in the elderly.  
13 Standardised mortality ratio (SMR) for myocarditis was 1.35 (0.84 to 2.55) for those 60 years or  
14 older and 1.69 (1.18 to 2.42) in overall age. The risk of myocarditis mortality in the SARS-CoV-2  
15 vaccinated population may be 4 times or higher than the apparent MMRRs considering healthy  
16 vaccinee effect. Unreported post-vaccination deaths should also be considered as suggested by the  
17 extremely high myocarditis mortality odds ratio (148.49; 89.18 to 247.25).

18

1 **ABSTRACT**

2 **Objective:** To investigate the association between SARS-CoV-2 vaccination and myocarditis death

3 **Design:** Population based comparative mortality study

4 **Setting:** Japan

5 **Participants:** Vaccinated population was 99 834 543 individuals aged 12 years and older who have  
6 been received SARS-CoV-2 vaccine once or twice by 14 February 2022. Reference population was  
7 defined persons aged 10 years and older from 2017 to 2019.

8 **Main outcome measures:** The primary outcome was myocarditis death, defined as the case with  
9 "myocarditis" for primary cause of death and with onset 28 days or less after vaccination disclosed  
10 on 11 November 2022. Myocarditis mortality rate ratio (MMRR) of the SARS-CoV-2 vaccinated to  
11 the reference population by 10-year age group and standardised mortality ratio (SMR) were  
12 calculated. Mortality odds ratios (MORs) by 10-year age group were also calculated for  
13 supplementary analysis. Healthy vaccine effect-adjusted MMRRs (adMMRRs) or adjusted SMR  
14 (adSMR) were calculated by dividing MMRRs or SMR by 0.24 respectively.

15 **Results:** Number of myocarditis death which met the inclusion criteria were 32 cases. MMRR (95%  
16 confidence interval) was 4.03 (0.77 to 13.60) in 20s, 7.80 (2.85 to 18.56) in 30s, respectively. SMR  
17 of myocarditis was 1.69 (1.18 to 2.42) for overall vaccinated population, 1.35 (0.84 to 2.55) for  
18 those 60 years or older. Estimated adMMRRs and adSMR were about 4 times higher than the  
19 MMRRs and SMR. Pooled MOR for myocarditis were 148.49 (89.18 to 247.25).

20 **Conclusion:** SARS-CoV-2 vaccination was associated with higher risk of myocarditis death, not  
21 only in young adults but also in all age groups including the elderly. Considering healthy vaccinee  
22 effect, the risk may be 4 times or higher than the apparent risk of myocarditis death. Underreporting  
23 should also be considered. Based on this study, risk of myocarditis following SARS-CoV-2  
24 vaccination may be more serious than that reported previously.

25

## 1 INTRODUCTION

2 Amongst the several safety concerns of SARS-CoV-2 vaccination, myocarditis is one of the most  
3 important adverse reactions which package insert warn as “Post marketing data demonstrate  
4 increased risks of myocarditis and pericarditis”.<sup>1 2</sup> After a notification of a possible link between  
5 SARS-CoV-2 vaccination and myocarditis by the US Centers for Disease Control and Prevention  
6 (CDC),<sup>3</sup> a number of case reports have been published<sup>4</sup> and several fatal cases have also been  
7 published.<sup>5-12</sup> In Japan, a 27-year-old professional athlete with no history of symptomatic illness  
8 except orthopedic problem was rushed to hospital with cardiac arrest on day eight of the first dose  
9 of mRNA-1273 (Moderna) vaccine and subsequently died, with autopsy results revealing  
10 myocarditis.<sup>12</sup> A non-comparative epidemiological study indicated that the highest incidence of  
11 myocarditis was reported in male patients between the ages of 16 and 29 years.<sup>13</sup> Comparative  
12 epidemiological studies showed that SARS-CoV-2 vaccination is associated with increased risk of  
13 myocarditis especially in adolescent and young adults without exception.<sup>14-18</sup> However, they  
14 reported that myocarditis after vaccination was mild<sup>14 16</sup> and did not focus on the fatal cases.<sup>14-18</sup>  
15 The package inserts of SARS-CoV-2 vaccine do not mention the possibility of death from  
16 myocarditis after the vaccination.<sup>1 2</sup> To our best knowledge, no epidemiological studies have  
17 conducted to investigate the association of increased risk of SARS-CoV-2 vaccine on myocarditis  
18 death.

19 The primary objective of this study is to investigate association between SARS-CoV-2 vaccine and  
20 myocarditis deaths comparing mortality rate with general population, then to provide a new  
21 discussion on the healthy vaccinee effect in using SARS-CoV-2 vaccine, especially on death. In  
22 addition, all-cause death after vaccination was also investigated and under-reporting of deaths was  
23 discussed.

24

## 25 METHODS

26 This study compared myocarditis mortality rate in the SARS-CoV-2 vaccinated with that in the  
27 general population in Japan. The study was based on the materials and the vital statistics disclosed  
28 by the Japanese government.

29

### 30 Data sources and case definition

31

#### 32 1. Vaccinated population

33 The vaccinated population was defined as those who had received the first or the second doses of  
34 SARS-CoV-2 vaccine since the start of the vaccination program (17 February 2021) until 14  
35 February 2022. The number of persons received vaccine by number of doses was disclosed by the  
36 Japanese Cabinet Office by 10-year age group without background information for sex, vaccine type  
37 and others.<sup>19</sup> According to this information, 99 834 543 persons received the first dose and 99 117  
38 143 persons received the second dose. Of the Japanese population aged 12 years or older, 89.6%

1 received at least one dose of SARS-CoV-2 vaccine.

2 The number of vaccinated populations by number of doses, by vaccine type for all age groups  
3 combined was also disclosed.<sup>20</sup> This information was used to estimate the interval between the first  
4 and the second dose. The discrepancy between the total number of vaccinees by age group and the  
5 total number of vaccinees by vaccine type may be due to the presence of vaccination cases of  
6 unknown age group at the time of reporting.

7

## 8 **2. Death cases after receiving SARS-CoV-2 vaccine**

9 Data for the death cases after receiving SARS-CoV-2 vaccine were based on “the summary list of  
10 death cases after SARS-CoV-2 vaccination” as pdf files that were disclosed by the panels of experts  
11 on vaccination and adverse reactions under Japan’s Ministry of Health, Labour and Welfare  
12 (MHLW) at 11 November 2022.<sup>21-23</sup> The list include age, sex, number of vaccination, last  
13 vaccinated date, comorbidities, histories leading to death, cause of death diagnosed by physician,  
14 corresponding MedDRA terms, tests for the base of diagnosis, causal assessment by physician,  
15 assessment by the experts (Fig S1). Both authors independently converted the pdf data into excel  
16 files and confirmed data matched. Total number of death cases reported by 9 October and disclosed  
17 on 11 November was 1 897 (Fig 1).

18 In Japan, doctors are required to report serious adverse reactions to vaccine in general including  
19 death within 28 days if they suspected an association with vaccination.<sup>24</sup> For SARS-CoV-2 vaccine,  
20 those occurred during the period considered by a physician as highly relevant to vaccination were  
21 required to report at the beginning of the vaccination program.<sup>24</sup> Subsequently, physicians were  
22 required active consideration of reporting myocarditis, pericarditis and thrombosis occurring within  
23 28 days after vaccination if they suspected an association with vaccination.<sup>25</sup> Therefore, we defined  
24 the death cases for comparison of mortality rate as those in which the onset (start of signs and  
25 symptoms leading to death) was known as occurred within 28 days after the last dose of  
26 SARS-CoV-2 vaccine (reasons for inclusion of onset within 28 days are explained later in detail).  
27 We restricted the vaccinee who received one or two dose and excluded those with third or fourth  
28 dose to avoid further healthy vaccinee effect.<sup>26 27</sup> Number of included death cases was 1 374 in total  
29 (Fig 1).

30

## 31 **3. Myocarditis death after SARS-CoV-2 vaccination**

32 “Myocarditis death case” after vaccination was defined as the cases in which “myocarditis” was  
33 described in the cause of death column of the above summary list, regardless of diagnostic method.  
34 When more than one cause of death was listed, we extracted cases where “myocarditis” was listed  
35 as the primary cause of death. They were classified as death from I40 (acute myocarditis) under the  
36 10th revision of the International Statistical Classification of Diseases and Related Health Problems  
37 (ICD-10).

38 On the 11 November 2022 list, number of included myocarditis death reports was 32, of which 22

1 were on the 18 February 2022 list and 10 new deaths were added since then.

2 Diagnostic bases for myocarditis are classified according to the information on the summary list of  
3 death cases disclosed on 11 November 2022 as follows: 1. Autopsy and/or myocardial biopsy, 2.  
4 Elevated Troponin with blood test, 3. Other blood test and/or (ECG and/or UCG), 4. Only symptoms.  
5 Diagnostic basis for the lower number does not include the diagnostic basis for the higher number.

6

#### 7 **4. Calculation of person-years of exposure for vaccinated population**

8 Average days from first to second dose are different among three products: 21 days for BNT162b,<sup>1</sup>  
9 28 days for mRNA-1273,<sup>2</sup> and 40 days for ChAdOx1 nCoV-19.<sup>28 29</sup> The number of second dose  
10 were 84 023 380 for BNT162b, 16 090 036 for mRNA-1273, and 58 300 for ChAdOx1 nCoV-19  
11 (Table S1). However, the number of doses by age group and by vaccine type was not disclosed.  
12 Therefore, weighted average days from first to second dose for overall ages was estimated as 22.14  
13 days in overall ages (Table S2).

14 Based on the above information, the person-years of observation for the first dose and the second  
15 dose were calculated as follows:  $D = (A \times 22.14 + B \times 5.86) / 365$ ,  $E = C \times 28 / 365$ ,  $F = D + E$ . where  
16 22.14 is the weighted average days from the first dose to the second dose and 5.86 is 28 days of  
17 observation period - 22.12, A is the number of vaccinees who received the first dose, B is that with  
18 only the first dose, C is that with the second dose, D is the person-years for the first dose, E is for  
19 the second dose and F is total person-years.

20

#### 21 **5. Reference population and death**

22 We chose the general Japanese population during the period from 2017 through 2019 in the  
23 pre-COVID-19 pandemic era as reference population and death for comparison based on the vital  
24 statistics in 2017, 2018 and 2019.

25 Myocarditis mortality rates in the reference population were calculated from the total number of  
26 myocarditis deaths by total population by 10-year age groups in three years from 2017 to 2019.<sup>30-35</sup>

27

#### 28 **Outcome measures and statistical analyses**

29 Primary outcome measure was myocarditis mortality rate. We compared the observed mortality  
30 rate of myocarditis with the expected mortality rate using data for reference population. Myocarditis  
31 mortality rate ratios (MMRRs) and their 95% confidence intervals (95% CIs) by 10-year age group  
32 were calculated.

33 Sensitivity analysis was performed as follows:

- 34 1) Standardised mortality ratio (SMR) for overall age stratified by 10-year age groups.
- 35 2) SMRs for 3 age groups (12-39, 40-59 and 60 or older) stratified by 10-year age groups.
- 36 3) SMR by the vaccination status after the first or second dose.
- 37 4) SMR for all-cause death.

1 5) Mortality odds ratio (MOR) by 10-year age group for myocarditis applying reporting odds ratio  
2 (ROR).<sup>36</sup>  
3 6) MMRRs and SMR adjusted by the healthy vaccinee effect were estimated: Healthy vaccinee  
4 effect by SARS-CoV-2 vaccination expressed as the rate ratio of mortality rate in vaccinated to that  
5 in the reference general population was shown approximately as 0.10 to 0.24 (95% CI were not  
6 given).<sup>26 27</sup> An approximate healthy vaccinee effect-adjusted MMRRs (adMMRRs) or adjusted  
7 SMR (adSMR) were yielded by dividing MMRRs or SMR by 0.10 to 0.24 respectively without 95%  
8 CI, by applying the prior event rate ratio (PERR) adjustment method for “unmeasured confounding”  
9 in observational studies.<sup>37-39</sup>

10

11 The valid reasons for comparing myocarditis mortality rate of vaccinee with onset within 28 days  
12 from the last dose and of the reference population are based on the following. In the reference  
13 population, death cases in which signs and symptoms of myocarditis leading to death develop  
14 during the observation period (From the beginning through the end of the year) and die after the  
15 observation period are not included in the mortality calculation, whereas cases that develop before  
16 the observation period and die during the observation period are included in the mortality  
17 calculation (Fig S2a).

18 In the post-vaccination population, on the other hand, a case in which signs and symptoms of  
19 myocarditis leading to death had already developed before vaccination would have never been  
20 reported as a death case possibly or probably associated with vaccine and is never included in the  
21 mortality analysis. Hence, cases in which signs and symptoms of myocarditis leading to death  
22 develop during the observation period should be included in the mortality analysis among  
23 vaccinated population for fair comparison with the reference population (Fig S2b).

24 Using the same method, number of all-cause deaths in the post-vaccinated population was  
25 calculated and compared with the expected number of deaths from all-cause.

26 All statistical analyses were performed with Stats Direct (Version 3.3.5). The significance level  
27 was set at  $P < 0.05$ . Statistical multiplicity was not tested because this is rather an exploratory study  
28 but not a hypothesis confirming study.

29 Ethical approval was not obtained for this study because it was based on the disclosed data and is  
30 not required to obtain ethics approval under Japanese law and guidelines.

31

## 32 **Patient and Public involvement**

33 Patients and public were not involved in the design, analyses, in this study because the research  
34 agenda was urgent.

35

## 36 **RESULTS**

37 The number of included death cases for analysis was 1 374 including 32 myocarditis death and  
38 their characteristics are shown in Table 1.



1 Persons who died from myocarditis death were younger, used more mRNA-1273 and occurred  
2 more after the second dose than those from other causes after SARS-CoV-2 vaccination.  
3 Myocarditis was diagnosed by autopsy and/or myocardial biopsy in half cases.  
4 Table 2 shows the number of vaccinated persons by age and the person-years of observation  
5 calculated from them. Table 3 shows the population, causes of death, and their crude mortality rates  
6 for 2017-2019, used as reference. Details for each year are shown in the Table S3.

### 8 **Myocarditis mortality in SARS-CoV-2 vaccinated population compared with reference** 9 **population**

10 MMRRs and their (95%CI) after receiving SARS-CoV-2 vaccine were 4.03 (0.77 to 13.60) in 20s,  
11 7.80 (2.85 to 18.56) in 30s. Except 10s and 50s and 60s, each point estimates of the MMRR  
12 exceeded 1.00. Crude MMRR was 1.77 (1.19 to 2.53) for overall vaccinated population, 1.62 (0.85  
13 to 2.79) after the first dose and 1.79 (1.05 to 2.85) after the second dose.

14 SMR of myocarditis was 1.69 (1.18 to 2.42) for overall vaccinated population, 1.53(0.88 to 2.66)  
15 after the first dose and 1.72(1.07 to 2.76) after the second dose. Details were shown in Fig 2 and  
16 Table 4. SMR of myocarditis in those aged 12-39, 40-59 and the elderly overall (60 years or older)  
17 was 4.52 (2.32 to 8.82), 1.01 (0.37 to 2.74) and 1.35 (0.84 to 2.17), respectively.

### 18 19 **All-cause mortality in SARS-CoV-2 vaccinated population**

20 The apparent rate ratios for all-cause death after receiving SARS-CoV-2 vaccine were shown in  
21 Table S4. The apparent SMR for all-cause mortality was 0.01.

### 22 23 **Mortality odds ratio for myocarditis**

24 Age-stratified and pooled MORs for myocarditis death after receiving SARS-CoV-2 vaccine were  
25 shown in Table S5. Except 10s in which reported myocarditis death were zero, point estimates  
26 MORs for myocarditis were above 20. The crude MOR was 209.82 (146.06 to 301.41), and the  
27 pooled MOR (95% CI) for myocarditis death was 148.49 (89.18 to 247.25).

### 28 29 **Healthy vaccinee effect adjusted MMRRs**

30 Estimated point adMMRRs were approximately 17 to 40 in 20s, 33 to 80 in 30s, and adSMR was 7  
31 to 17 in overall vaccinated population (95%CI were not calculated).

## 32 33 **DISCUSSION**

### 34 35 **Principal findings**

36 Using the disclosed data by the Japanese government, we observed increased myocarditis mortality  
37 rate ratio in the SARS-CoV-2 vaccinated population compared with general population during three  
38 years pre-COVID-19 pandemic era, especially in young adults (MMRR: 7.80 in 30s). However, not

1 only in young adults, but also in the elderly and overall vaccinated, increased risk of myocarditis  
2 death is associated with vaccination even without consideration of healthy vaccinee effect. The  
3 pooled MOR for myocarditis death was as high as 148.49. Very rough estimation of healthy  
4 vaccinee effect adjusted MMRRs showed as high as 33 to 80 in 30s and about 7 to 17 for adSMR  
5 which were closer to pooled MOR. Increased risk was higher after the second dose than the first  
6 dose as shown in previous epidemiologic studies focusing on hospitalised myocarditis patients.<sup>14-18</sup>  
7

### 8 **Strengths of this study**

9 This study has several strengths. First this is the first epidemiological study that show the  
10 increased risk of myocarditis mortality after the SARS-CoV-2 vaccination. Previous  
11 epidemiological studies which reported the increased risk of myocarditis did not report the  
12 increased death from myocarditis<sup>14-18</sup> with emphasis that most cases were mild,<sup>14 16</sup> that deaths  
13 were rare with no deaths of persons younger than 40 years<sup>17</sup> and that one person died with  
14 fulminant myocarditis in the nationwide Israeli study.<sup>14</sup>

15 Patone et al.<sup>40</sup> conducted a self-controlled case series study focusing on incidence but not on  
16 mortality from myocarditis following vaccination. However, using their data<sup>40</sup> and the statistics of  
17 England,<sup>41 42</sup> we found similar evidence of increased risk of myocarditis mortality in SARS-CoV-2  
18 vaccinated population as shown in our study.

19 In their paper,<sup>40</sup> there was the number of persons received SARS-CoV-2 vaccine in the Table 1;  
20 there was the number of myocarditis deaths occurred within 1-28 days after receiving vaccine in the  
21 Supplementary Table 1.<sup>40</sup> Sixty-one myocarditis deaths have been observed during an overall  
22 observation period of 54.24 (100 000 person-years) for the entire vaccinated population aged 16  
23 years and older; hence myocarditis mortality rate was 1.12 per100 000 person-years for the  
24 post-vaccinated population. In the three-year period from 2017 to 2019, the observation period of  
25 England aged 15 years and older was 1 375 (100 000 person-years),<sup>41</sup> during which 552 deaths for  
26 myocarditis<sup>42</sup> were observed (myocarditis classification in England is different from Japanese  
27 classification). The myocarditis mortality rate from 2017 to 2019 in England was therefore 0.40 per  
28 100 000 person-years. Based on these data, crude MMRR in England would be 2.80 (2.11 to 3.65) if  
29 calculating by the same method of ours.

30 Other study with the most vaccinated population was a study of approximately 19 million persons  
31 in four Nordic countries.<sup>17</sup> Although some parts of the discussion and Supplementary Content in  
32 their article referred to deaths, their study was not primarily aimed at investigating post-vaccination  
33 myocarditis deaths. In their study, about 6 million of those vaccinated were under 39 years of age,  
34 about one-fifth of those in this study; therefore, it may be difficult to detect an increase in  
35 myocarditis deaths among younger subjects.

36 Second, we revealed increase risk of myocarditis death in all age groups even without  
37 consideration of healthy vaccinee effect.

38 Third, we pointed out that if healthy vaccinee effect was considered, the risk of SARS-CoV-2

1 vaccine on myocarditis death may be much higher, with rate ratio up to 33 to 80 in 30s.

2 Fourth in addition, we showed that pooled MOR is extremely high although it is assumed that  
3 reports of cases with myocarditis after SARS-CoV-2 vaccine may be enhanced because it was  
4 widely reported in the media.

5 Fifth these results indicated that myocarditis mortality is increased in vaccinated persons and  
6 provide important insights into the consideration of benefits and harms of the SARS-CoV-2 vaccine.

7

### 8 **Limitations of this study**

9 This study has several limitations. First, diagnosis of myocarditis death after SARS-CoV-2 vaccine  
10 was based on the physician's diagnosis and was not based on exactly the newly proposed Brighton's  
11 case definition.<sup>43</sup> However, 50 % of myocarditis cases were diagnosed by autopsy and/or  
12 myocardial biopsy. They are exactly the level 1 myocarditis (definite case) by the Brighton's case  
13 definition. Including above definite cases, almost 90% of cases were diagnosed at least blood test  
14 and/or ECG and/or UCG. Cases based on symptoms only or unknown methods were 11%. Moreover,  
15 diagnostic base of the myocarditis death in the reference population from 2017 to 2019 was not  
16 known and was also based on physician's diagnosis. Previous studies<sup>14-18</sup> supported a high  
17 incidence of post- SARS-CoV-2 vaccination myocarditis, making it difficult to consider that  
18 diagnostic accuracy is a factor in overestimating myocarditis mortality after vaccination. As  
19 described in the strengths of this study, the risk of myocarditis mortality following vaccination in  
20 the 2017-2019 population in England may be 2.80 (2.11 to 3.65) as a crude MMRR. In contrast, in  
21 this study, the crude MMRR was 1.77 (1.19 to 2.53) which is similar to the SMR and even lower  
22 than that in England.

23 Second, because myocarditis after SARS-CoV-2 vaccine received media attention, it is likely that  
24 physicians paid more attention and reported more. It might be one of the reasons for extremely high  
25 pooled MOR for myocarditis death. However, this may be resulted from underreporting of death  
26 from other causes, because not all deaths after SARS-CoV-2 vaccine were reported. There is no  
27 obligation to report all post-vaccination deaths in Japan, therefore only those cases where a  
28 physician suspected association to vaccination are reported and disclose by the MHLW. In the  
29 United States (US), 610 million doses of the SARS-CoV-2 vaccine had been administered until 31  
30 August 2022, and about 16 000 post-vaccination deaths had been reported,<sup>44</sup> while in Japan, only  
31 about 1 500 post SARS-CoV-2 vaccination deaths had been disclosed against 200 million doses of  
32 the vaccine until 14 February 2022. If post-vaccination deaths were reported on a par with the US,  
33 this could be about 3.5 times higher. The apparent SMR for all-cause deaths were as low as 0.01. It  
34 is far lower than those estimated by other data. For example, randomized control trials have shown  
35 that the SARS-CoV-2 vaccine was not effective in reducing all-cause death.<sup>45 46</sup> The results of  
36 analysis<sup>26 47</sup> using data of UK statistics<sup>48</sup> showed that age adjusted non-COVID-19 mortality rate in  
37 the ever vaccinated compared with that in the general population was estimated at 0.61 in January  
38 2021. These results indicate that there was substantial underreporting of SARS-CoV-2

1 post-vaccination deaths. Mevorach revealed that the risk of myocarditis morbidity after vaccination  
2 was highest among second-time vaccinators aged 16-19 years.<sup>14</sup> On the other hand, Japan's MHLW  
3 database had not yet listed any myocarditis deaths between the ages of 12 and 19 years.  
4 Subsequently, vaccination of people aged 5-11 years began in Japan, and as of 11 November 2022,  
5 one person had died from myocarditis.<sup>49</sup>

6 Third, SMR was only adjusted for age, MMRRs and SMR were not adjusted for sex and for other  
7 factors such as calendar period, health care worker status, nursing home resident, and comorbidities  
8 like Husby et al.<sup>16</sup> and/or Karlstad et al.<sup>17</sup> Mevorach et al, who compared the incidence of  
9 myocarditis between the three-year period 2017-2019 and the post-vaccination population in Israel,  
10 also stated that they had not adjusted for factors other than age and sex as a limitation of their study.  
11 However, to our best knowledge, obvious confounding factors<sup>50</sup> were not found that would  
12 overestimate myocarditis mortality following SARS-CoV-2 vaccination in this study. A cohort study  
13 by Karlstad et al.<sup>17</sup> investigated the incidence of myocarditis in vaccinated and unvaccinated groups;  
14 we could compare of crude incidence rate ratios (IRRs) and adjusted IRRs using the data (Table 2  
15 and eFigure2 in their paper). Even if the model with the lowest adjusted IRR was adopted (Adjusted  
16 by age group, sex, previous SARS-CoV-2 infection, healthcare worker, nursing home resident,  
17 comorbidity, and calendar time), the adjusted IRR was about 0.77 to 0.98 times compared to the  
18 crude IRR (2 to 23 % decrease from crude IRR). It does not extend to the impact of the  
19 underestimation of post-vaccination myocarditis mortality by healthy vaccine effect  
20 (underestimation by 0.10 to 0.24). Hence, the MMRRs and SMR may not be overestimated by this  
21 limitation.

22 Forth, we could not compare relative risk among products, BNT162b2 (Pfizer-Biotech) or  
23 mRNA-1273 (Moderna), because precise data for number of persons who received each product by  
24 age group until the cut off day (14 February 2022) were not disclosed. However, according to the  
25 analysis by National Institute of infectious diseases,<sup>51</sup> proportion of reports for myocarditis among  
26 male 10s and 20s who received second dose of mRNA-1273 was 102.1 and 47.2 per million persons  
27 respectively, while 15.4 and 10.0 per million persons for second dose of BNT162b2. If the  
28 distribution of number of persons who received each product by age group at the cut off day (14  
29 February 2022) were the same as reported on 3 December 2021, mortality rate ratio from  
30 myocarditis among those who were younger than 40 years and received mRNA-1273 compared with  
31 those who received BNT162b2 show no significant increase: 3.12 (95%CI: 0.84 to 11.63,  $P=0.073$ ),  
32 while it was not significant among those 40 years or older.

33 Fifth, we have no direct evidence on healthy vaccinee effect of SARS-CoV-2 vaccine in Japan.  
34 However, there are more than one evidence that indicates healthy vaccinee effect of SARS-CoV-2  
35 vaccine in the world. One<sup>26 47</sup> is the results of analysis using data from UK statistics<sup>52</sup> and the other  
36<sup>27 44</sup> is the results of analysis using the published data in the peer review journal.<sup>53 54</sup>

37 According to the former analysis, COVID-19-related mortality rate ratio (MRR) of those who died  
38 21 days or more after the second dose to the unvaccinated was 0.02 at the beginning of the

1 immunization program in UK (January 2021), while the non-COVID-19 MRR of those who died 21  
2 days or more after the second dose to the unvaccinated was 0.11 (95%CI: 0.08 to 0.14) for January  
3 2021 and 0.13 (0.10 to 0.17) for February 2021. These indicate that healthy vaccinee effect may  
4 work to lower the apparent risk of death from COVID-19 and may increase the apparent  
5 effectiveness of SARS-CoV-2 vaccine. Dividing the COVID-19-related MRR of 0.02 by the  
6 non-COVID-19 MRR of 0.11, yields a healthy vaccinee effect-adjusted COVID-19-related MRR of  
7 0.18 (95%CI: 0.09 to 0.37). This may be considered to be closer to the true COVID-19-related  
8 MRR.<sup>26</sup>

9 Under similar conditions to this study, the healthy vaccinee effects estimated using UK statistics  
10 are as follows. Healthy vaccinee effect by SARS-CoV-2 vaccination expressed as MRR in ever  
11 vaccinated to expected mortality rate for 2021 assuming that COVID-19 is not epidemic in England  
12 and Wales (932.1/100 000 person years) was estimated 0.61 in January 2021 and 0.10 to 0.24 at the  
13 day of vaccination, by applying the analysis results<sup>27</sup> using data from Israeli study,<sup>53</sup> as shown in  
14 the following another evidence.

15 The analysis results show that odds ratio (OR) of symptomatic COVID-19 on day 1 of vaccination  
16 was 0.40 (95%CI: 0.31 to 0.51) and ORs of hospitalisation, severe COVID-19 and death due to  
17 COVID-19 on day 1 are roughly estimated as 0.27, 0.18 and 0.13 respectively (95%CI was not  
18 calculated).<sup>27</sup> Vaccination can never work at the day of vaccination; these low risk of mortality and  
19 morbidity is highly probably derived from the fact that the vaccinated people were much healthier  
20 than the unvaccinated. This bias could not be adjusted by ordinary methods for matching by  
21 adjusting age, sex, sector, and residence, history of influenza vaccination, pregnancy and total  
22 number of coexisting risk factors that Dagan et al used. This bias is a sort of “unmeasured  
23 confounding” in observational studies that Tannen et al proposed to adjust by the prior event rate  
24 ratio (PERR).<sup>37-39</sup>

25 Theoretical basis of healthy vaccinee effect was shown by Fine et al.<sup>55</sup> Jackson et al<sup>56</sup> reported  
26 that the relative risk of death, hospitalisation due to pneumonia and ischemic heart disease for  
27 influenza vaccinated persons compared with unvaccinated persons was 0.36 (95%CI: 0.30 to 0.44),  
28 0.65 (0.53 to 0.80) and 0.92 (0.83 to 1.02) before influenza season respectively in the United States.  
29 They concluded that the reductions in risk before influenza season indicate preferential receipt of  
30 vaccine by relatively healthy seniors and adjustment for diagnosis code variables did not control for  
31 this bias<sup>53</sup> just as in the Dagan’s study<sup>53</sup> and Tannen et al.<sup>37-39</sup>

32 These results indicate that the more serious the disease, the lower the apparent risk of vaccination  
33 and are consistent with the results of analysis<sup>27</sup> on Dagan’s data.<sup>53</sup>

34 In fact, Husby et al<sup>16</sup> mentioned the fact that SARS-CoV-2 vaccines are rarely given to people  
35 with an acute or terminal illness as a likely explanation of low 28-day risk of cardiac arrest or death  
36 in their study. This explanation is exactly the “healthy vaccinee effect”.

37 Considering these, healthy vaccinee effect works in the direction of positive for vaccination (more  
38 effective and safer) universally on observational studies even if many variables were matched

1 and/or adjusted by the ordinary methods used in most observational studies including propensity  
2 score matching. Hence, it may be rational to take the health vaccinee effect into account in the  
3 present study. Because death is a rare event, the extent of the healthy vaccinee effect on death which  
4 were estimated using previously disclosed data showed wide range (0.10 to 0.24). If the least  
5 healthy vaccinee effect (the highest MRR: 0.24) is used, risk of SARS-CoV-2 vaccine on  
6 myocarditis death is estimated about 4 times higher than those without adjustment.

7 Lastly, this study is rather an exploratory study but not a hypothesis confirming study. However,  
8 we found several strong associations especially in the age of 30s even without adjustment for  
9 healthy-vaccinee effect and that very high MMRR were estimated if they were adjusted for  
10 healthy-vaccinee effect. Moreover, we got very high age-stratified and pooled MOR for myocarditis  
11 death. Hence, we discuss the causal inference on the increased myocarditis mortality and  
12 SARS-CoV-2 vaccine use primarily according to the modified criteria of US Advisory Committee to  
13 the Surgeon General<sup>57</sup> (modified US Surgeon General criteria) with some supplementary discussion  
14 using viewpoints of causation by Hill<sup>58</sup> (Hill's viewpoints) (Table S6). Because “specificity of  
15 association” both in US Surgeon General criteria and Hill's viewpoints is an extreme type of  
16 “strength of association”, we included it into “strength of association” and classified into 4 criteria:  
17 (1) temporarily, (2) consistency, (3) strength and (4) coherence of association.

18 We found all 4 criteria were satisfied and we conclude that the association of high myocarditis  
19 mortality rate ratio after SARS-CoV-2 vaccination may be causal.

20

### 21 **Points to be clarified in future research.**

22 Post-vaccination death should be more precisely investigated, not only from myocarditis but also  
23 from other causes. These should be closely monitored by nation-wide investigation as done in  
24 England and Wales or in the country with larger population. In these investigations, “healthy  
25 vaccinee effect” must be taken into account.

26

### 27 **Conclusions and policy implications**

28 Despite above limitations, this study revealed that SARS-CoV-2 vaccination was associated with  
29 higher mortality rate from myocarditis, especially in young adults compared with 2017 to 2019  
30 population. But it also revealed that myocarditis death occurs in older persons. If healthy vaccinee  
31 effect is taken into account, the risk increases at least approximately 4 times more than the  
32 unadjusted mortality risk. In addition, underreporting deaths after receiving vaccine should be  
33 considered. Based on the results of this study, it is necessary to inform public about that the risk of  
34 serious myocarditis including death may be far more serious than the risk reported before and that it  
35 occurs not only in young persons but also in elderly.



## 1 **References**

2

3 1. SARS-CoV-2 vaccine package insert of BNT162b2 (Pfizer-BioNTech)

4 Available at: <https://www.fda.gov/media/151707/download> (Accessed 13 September 2022)

5

6 2. SARS-CoV-2 vaccine package insert of mRNA-1273 (Moderna).

7 Available at: <https://www.fda.gov/media/157233/download> (Accessed 13 September 2022)

8

9 3. Centers for Disease Control and Prevention of the United States (CDC). COVID-19 VaST Work  
10 Group Report - May 17, 2021

11 Available at: <https://www.cdc.gov/vaccines/acip/work-groups-vast/report-2021-05-17.html>

12 (Accessed 13 September 2022)

13

14 4. Behers BJ, Patrick GA, Jones JM, et al. Myocarditis Following COVID-19 Vaccination: A  
15 Systematic Review of Case Reports. *Yale J Biol Med* 2022; 95(2):237-47. PMID: 35782472

16

17 5. Choi S, Lee S, Seo JW, et al. Myocarditis-induced Sudden Death after BNT162b2 mRNA  
18 COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. *J  
19 Korean Med Sci* 2021; 36(40): e286. doi: 10.3346/jkms.2021.36. e286

20

21 6. Abbate A, Gavin J, Madanchi N, et al. Fulminant myocarditis and systemic hyperinflammation  
22 temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. *Int J  
23 Cardiol* 2021; 340:119-21. doi: 10.1016/j.ijcard.2021.08.018

24

25 7. Verma AK, Lavine KJ, Lin CY. Myocarditis after Covid-19 mRNA Vaccination. *N Engl J Med*  
26 2021; 385(14):1332-34. doi: 10.1056/NEJMc2109975

27

28 8. Khogali F, Abdelrahman R. Unusual Presentation of Acute Perimyocarditis Following  
29 SARS-COV-2 mRNA-1237 Moderna Vaccination. *Cureus* 2021; 13(7): e16590.

30 doi: 10.7759/cureus.16590

31

32 9. Lim Y, Kim MC, Kim KH, et al. Case Report: Acute Fulminant Myocarditis and Cardiogenic  
33 Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal  
34 Cardiopulmonary Resuscitation. *Front Cardiovasc Med* 2021; 8:758996.

35 doi: 10.3389/fcvm.2021.758996

36

37 10. Ameratunga R, Woon ST, Sheppard MN, et al. First Identified Case of Fatal Fulminant  
38 Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA

- 1 COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity  
2 Reaction. *J Clin Immunol* 2022; 42(3):441-47. doi: 10.1007/s10875-021-01187-0  
3
- 4 11. Gill JR, Tashjian R, Duncanson E. Autopsy Histopathologic Cardiac Findings in 2 Adolescents  
5 Following the Second COVID-19 Vaccine Dose. *Arch Pathol Lab Med* 2022; 146(8):925-29.  
6 doi: 10.5858/arpa.2021-0435-SA  
7
- 8 12. Hoshino N, Yanase M, Ichiyasu T, et al. An autopsy case report of fulminant myocarditis:  
9 Following mRNA COVID-19 vaccination. *J Cardiol Cases* 2022  
10 doi: 10.1016/j.jccase.2022.06.006  
11
- 12 13. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health  
13 Care Organization. *N Engl J Med* 2021; 385(23):2132-39. doi: 10.1056/NEJMoa2110737  
14
- 15 14. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against  
16 Covid-19 in Israel. *N Engl J Med* 2021; 385(23):2140-49. doi: 10.1056/NEJMoa2109730  
17
- 18 15. Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA  
19 Vaccination. *JAMA* 2021; 326(14):1390-99. doi: 10.1001/jama.2021.15072  
20
- 21 16. Husby A, Hansen JV, Fosbol E, et al. SARS-CoV-2 vaccination and myocarditis or  
22 myopericarditis: population based cohort study. *BMJ* 2021; 375: e068665. doi:  
23 10.1136/bmj-2021-068665  
24
- 25 17. Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic  
26 Cohort Study of 23 Million Residents. *JAMA Cardiol* 2022 doi: 10.1001/jamacardio.2022.0583  
27
- 28 18. Patone M, Mei XW, Handunnetthi L, et al. Risk of Myocarditis After Sequential Doses of  
29 COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. *Circulation* 2022;  
30 146(10):743-54. doi:10.1161/CIRCULATIONAHA.122.059970  
31
- 32 19. Japan's Prime Minister's Office. SARS-CoV-2 vaccination results by age group until 14  
33 February 2022 [in Japanese]. Available at:  
34 <https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html> (Accessed 18 February 2022)  
35
- 36 20. Japan's Prime Minister's Office. Number of doses of SARS-CoV-2 vaccine per day by vaccine  
37 type [in Japanese].  
38 Available at: [https://www.kantei.go.jp/jp/content/vaccination\\_data5.pdf](https://www.kantei.go.jp/jp/content/vaccination_data5.pdf)



- 1 (Accessed 13 September 2022)
- 2
- 3 21. Japan's Ministry of Health, Labour and Welfare. meeting material No.1-3-1: "The summary list  
4 of death cases after SARS-CoV-2 vaccination (Comirnaty, Pfizer) for 11 November 2022  
5 meeting of the working group on adverse reactions to SARS-CoV-2 vaccine [in Japanese].  
6 Available at: <https://www.mhlw.go.jp/content/10601000/000961882.pdf>  
7 (Accessed 13 December 2022)
- 8
- 9 22. Japan's Ministry of Health, Labour and Welfare. meeting material No.1-3-2: "The summary  
10 list of death cases after SARS-CoV-2 vaccination (Spikevax, Moderna) for 11 November 2022  
11 meeting of the working group on adverse reactions to SARS-CoV-2 vaccine [in Japanese].  
12 Available at: <https://www.mhlw.go.jp/content/10601000/000961526.pdf>  
13 (Accessed 13 December 2022)
- 14
- 15 23. Japan's Ministry of Health, Labour and Welfare. meeting material No.1-3-3: "The summary list  
16 of death cases after SARS-CoV-2 vaccination (Vaxzevria, AstraZeneca)" for 11 November 2022  
17 meeting of the working group on adverse reactions to SARS-CoV-2 vaccine [in Japanese].  
18 Available at: <https://www.mhlw.go.jp/content/10601000/000961527.pdf>  
19 (Accessed 13 December 2022)
- 20
- 21 24. Japan's Ministry of Health, Labour and Welfare. meeting material No.2: -"On the setting of  
22 standard for reporting suspected adverse reactions to SARS-CoV-2 vaccine" for 15 February  
23 2022 meeting of the working group on adverse reactions to SARS-CoV-2 vaccine, [in Japanese].  
24 Available at: <https://www.mhlw.go.jp/content/10601000/000739053.pdf>  
25 (Accessed 8 October 2022)
- 26
- 27 25. Joint notification by the Director of the Health Service Bureau and the Director of the  
28 Pharmaceutical and Environmental Health Bureau, Ministry of Health, Labor and Welfare,  
29 dated 6 December 2021 "Partial revision of "Management of the reports of the suspected  
30 adverse reactions to routine vaccinations, etc." Available at:  
31 <https://www.mhlw.go.jp/content/000864024.pdf> (Accessed 9 October 2022)
- 32
- 33 26. Med Check editorial team. Non-COVID-19-related deaths were reduced in the vaccinated  
34 population Robust evidence for healthy vaccinee effect. *Med Check* 2022; 8(24): 24-31.  
35 Available at: <https://www.npojip.org/english/MedCheck/Med%20Check%20Tip-24-2022-9-25>  
36 (Accessed 27 September 2022)
- 37
- 38 27. Med Check editorial team. Why does vaccine look effective? Another evidence of healthy

- 1 vaccinee effect. *Med Check* 2022; 8(24): 33-37.  
2 Available at: <https://www.npojip.org/english/MedCheck/Med%20Check%20Tip-24-2022-9-25>  
3 (Accessed 27 September 2022)  
4
- 5 28. SARS-CoV-2 vaccine package insert of ChAdOx1 nCoV-19 (Astra Zeneca).  
6 Available at: [https://www.fda.gov/wp-content/uploads/2021/02/PI-for-COVID-19-Vaccine-](https://www.fda.gov/wp-content/uploads/2021/02/PI-for-COVID-19-Vaccine-AstraZeneca.pdf)  
7 [AstraZeneca.pdf](https://www.fda.gov/wp-content/uploads/2021/02/PI-for-COVID-19-Vaccine-AstraZeneca.pdf) (Accessed 13 September 2022)  
8
- 9 29. Japan's Ministry of Health, Labour and Welfare. Questions and answers about vaccination  
10 intervals for AstraZeneca vaccines [in Japanese]  
11 Available at: <https://www.cov19-vaccine.mhlw.go.jp/qa/0090.html>  
12 (Accessed 13 September 2022)  
13
- 14 30. Japan's Statistics Bureau of the Ministry of Internal Affairs and Communications. Population by  
15 Age (Single Year), Sex and Sex ratio - Total population, Japanese population, October 1, 2017  
16 (Table 1)  
17 Available at:  
18 [https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20170&month=0&tclass1=000001011679&result_back=1&tclass2val=0)  
19 [000000090001&cycle=7&year=20170&month=0&tclass1=000001011679&result\\_back=1&tcla](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20170&month=0&tclass1=000001011679&result_back=1&tclass2val=0)  
20 [ss2val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20170&month=0&tclass1=000001011679&result_back=1&tclass2val=0)  
21 (Accessed 13 September 2022)  
22
- 23 31. Japan's Statistics Bureau of the Ministry of Internal Affairs and Communications. Population by  
24 Age (Single Year), Sex and Sex ratio - Total population, Japanese population, October 1, 2018  
25 (Table 1)  
26 Available at:  
27 [https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20180&month=0&tclass1=000001011679&result_back=1&tclass2val=0)  
28 [000000090001&cycle=7&year=20180&month=0&tclass1=000001011679&result\\_back=1&tcla](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20180&month=0&tclass1=000001011679&result_back=1&tclass2val=0)  
29 [ss2val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20180&month=0&tclass1=000001011679&result_back=1&tclass2val=0)  
30 (Accessed 13 September 2022)  
31
- 32 32. Japan's Statistics Bureau of the Ministry of Internal Affairs and Communications. Population by  
33 Age (Single Year), Sex and Sex ratio - Total population, Japanese population, October 1, 2019  
34 (Table 1)  
35 Available at:  
36 [https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20190&month=0&tclass1=000001011679&result_back=1&tclass2val=0)  
37 [000000090001&cycle=7&year=20190&month=0&tclass1=000001011679&result\\_back=1&tcla](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20190&month=0&tclass1=000001011679&result_back=1&tclass2val=0)  
38 [ss2val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20190&month=0&tclass1=000001011679&result_back=1&tclass2val=0)

1 (Accessed 13 September 2022)

2

3 33. Japan's Ministry of Health, Labour and Welfare. Vital Statistics, 2017, Volume 3, 1-1. Deaths by  
4 cause (the list of three-character categories), sex and age (5-year age groups): Japan, 2017 (1)  
5 ICD-10 codes A-T

6 Available at:

7 [https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20170&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)  
8 [000001028897&cycle=7&year=20170&month=0&tclass1=000001053058&tclass2=000001053](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20170&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)  
9 [061&tclass3=000001053065&result\\_back=1&tclass4val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20170&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0) (Accessed 13 September 2022)

10

11 34. Japan's Ministry of Health, Labour and Welfare. Vital Statistics, 2018, Volume 3, 1-1. Deaths by  
12 cause (the list of three-character categories), sex and age (5-year age groups): Japan, 2018 (1)  
13 ICD-10 codes A-T.

14 Available at:

15 [https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20180&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)  
16 [000001028897&cycle=7&year=20180&month=0&tclass1=000001053058&tclass2=000001053](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20180&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)  
17 [061&tclass3=000001053065&result\\_back=1&tclass4val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20180&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0) (Accessed 13 September 2022)

18

19 35. Japan's Ministry of Health, Labour and Welfare. Vital Statistics, 2019, Volume 3, 1-1. Deaths by  
20 cause (the list of three-character categories), sex and age (5-year age groups): Japan, 2019 (1)  
21 ICD-10 codes A-T

22 Available at:

23 [https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20190&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)  
24 [000001028897&cycle=7&year=20190&month=0&tclass1=000001053058&tclass2=000001053](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20190&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0)  
25 [061&tclass3=000001053065&result\\_back=1&tclass4val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20190&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0) (Accessed 13 September 2022)

26

27 36. European Medicines Agency. Screening for adverse reactions in Eudra Vigilance.

28 Available at:

29 [https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-](https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf)  
30 [eudravigilance\\_en.pdf](https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf) (Accessed 13 September 2022)

31

32 37. Weiner MG, Xie D, Tannen RL. Replication of the Scandinavian Simvastatin Survival Study  
33 using a primary care medical record database prompted exploration of a new method to address  
34 unmeasured confounding. *Pharmacoepidemiol Drug Saf* 2008;17(7):661-70.

35 doi: 10.1002/pds.1585

36

37 38. Tannen RL, Weiner MG, Xie D. Replicated studies of two randomized trials of  
38 angiotensin-converting enzyme inhibitors: further empiric validation of the 'prior event rate ratio'

- 1 to adjust for unmeasured confounding by indication. *Pharmacoepidemiol Drug Saf*  
2 2008;17(7):671-85. doi: 10.1002/pds.1584  
3  
4  
5 39. Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug  
6 efficacy research on cardiovascular outcomes: comparison of database and randomised  
7 controlled trial findings. *BMJ* 2009;338: b81. doi: 10.1136/bmj. b81  
8  
9 40. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac  
10 arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nat Med*. 2021;  
11 28:410- 2. doi:10.1038/s41591-021-01630-0  
12  
13 41. Office for National Statistics. Estimates of the population for the UK, England and Wales,  
14 Scotland and Northern Ireland. Available at:  
15 [https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationesti](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland)  
16 [mates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland)  
17 (Accessed 12 December 2022)  
18  
19 42. Nomis official census and labour market statistics. Mortality statistics - underlying cause, sex  
20 and age. Available at:  
21 [https://www.nomisweb.co.uk/query/construct/summary.asp?mode=construct&version=0&datas](https://www.nomisweb.co.uk/query/construct/summary.asp?mode=construct&version=0&dataset=161#)  
22 [et=161#](https://www.nomisweb.co.uk/query/construct/summary.asp?mode=construct&version=0&dataset=161#) (Accessed 12 December 2022)  
23  
24 43. Sexson Tejtel SK, Munoz FM, Al-Ammouri I, et al. Myocarditis and pericarditis: Case  
25 definition and guidelines for data collection, analysis, and presentation of immunization safety  
26 data. *Vaccine* 2022; 40(10):1499-511. doi: 10.1016/j.vaccine.2021.11.074  
27  
28 44. Centers for Disease Control and Prevention of the United States (CDC). Reports of adverse  
29 events for the SARS-CoV-2 vaccine as of 31 August 2022.  
30 Available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html>  
31 (Accessed 13 September 2022)  
32  
33 45. Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA  
34 Covid-19 Vaccine through 6 Months *N Engl J Med* 2021; 385(19):1761-73.  
35 doi: 10.1056/NEJMoa2110345  
36  
37 46. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at  
38 Completion of Blinded Phase *N Engl J Med* 2021; 385(19):1774-85.

- 1       doi: 10.1056/NEJMoa2113017  
2
- 3       47. Hama R, Watanabe S. The risk of vaccination may be higher by considering “healthy vaccinee  
4       effect”. Available at: <https://www.bmj.com/content/375/bmj-2021-068665/rr-5>  
5       (Accessed 27 September 2022)  
6
- 7       48. Office for National Statistics, Dataset. Deaths by vaccination status, England: Available at:  
8       [https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datas  
9       ets/deathsbyvaccinationstatusengland](https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsbyvaccinationstatusengland) (Accessed 19 April 2022)  
10
- 11      49. Japan’s Ministry of Health, Labour and Welfare. meeting material No.1-3-4: “The summary list  
12      of death cases after SARS-CoV-2 vaccination (Comirnaty for 5 to 11 years old, Pfizer), for 5  
13      August 2022 meeting of the working group on adverse reactions to SARS-CoV-2 vaccine [in  
14      Japanese]. Working group on adverse reactions of vaccine. Available at:  
15      <https://www.mhlw.go.jp/content/10601000/000972982.pdf> (Accessed 13 September 2022)  
16
- 17      50. Rothman KJ. *Epidemiology: An Introduction*. Second ed. New York: Oxford University Press;  
18      2012.  
19
- 20      51. National Institute of infectious diseases. Characteristics of myocarditis-related events after  
21      SARS-CoV-2 vaccination reported as suspected post-vaccination adverse reaction reports from  
22      medical institutions. Reported on 18 February 2022 (in Japanese)  
23      Available at: <https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10984-covid19-75.html>  
24      (Accessed 13 September 2022)  
25
- 26      52. Data on COVID-19 (coronavirus) by Our World in Data, complete COVID-19 dataset (XLSX).  
27      Available at: <https://github.com/owid/covid-19-data/tree/master/public/data>  
28      (Accessed 2 October 2022)  
29
- 30      53. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass  
31      Vaccination Setting. *N Engl J Med* 2021; 384(15):1412-23. doi: 10.1056/NEJMoa2101765  
32
- 33      54. Magen O, Waxman JG, Makov-Assif M, et al. Fourth Dose of BNT162b2 mRNA Covid-19  
34      Vaccine in a Nationwide Setting. *N Engl J Med* 2022; 386(17):1603-14.  
35      doi: 10.1056/NEJMoa2201688  
36
- 37      55. Fine PEM, Chen RT. Confounding in Studies of Adverse Reactions to Vaccines. *Am J Epidemiol*  
38      1992; 136(2):121-35. doi: 10.1093/oxfordjournals.aje.a116479

- 1  
2 56. Jackson LA, Jackson ML, Nelson JC, et al. Evidence of bias in estimates of influenza vaccine  
3 effectiveness in seniors. *Int J Epidemiol* 2006; 35(2):337-44. doi: 10.1093/ije/dyi274  
4  
5 57. US Department of Health, Education, and Welfare Public Health Service. Smoking and Health:  
6 Report of the Advisory Committee to the Surgeon General of the United States. Public Health  
7 Service Publication No. 1103. 1964. Available at:  
8 <https://collections.nlm.nih.gov/ext/document/101584932X202/PDF/101584932X202.pdf>  
9 (Accessed 02 October 2022)  
10  
11 58. Hill AB. The environment and disease: association or causation? *Proc R Soc Med* 1965; 58:  
12 295-300. PMID: 14283879  
13  
14 59. Won T, Gilotra NA, Wood MK, et al. Increased Interleukin 18-Dependent Immune Responses  
15 Are Associated With Myopericarditis After COVID-19 mRNA Vaccination *Front Immunol* 2022;  
16 13: 851620. doi: 10.3389/fimmu.2022.851620  
17  
18 60. Decker MD, Garman PM, Hughes H, et al. Enhanced safety surveillance study of ACAM2000  
19 smallpox vaccine among US military service members. *Vaccine* 2021; 39(39): 5541-47. doi:  
20 10.1016/j.vaccine.2021.08.041  
21

1 **Figures and Tables**

2

3 **Figures**

4 Fig 1. Included death cases for analysis based on the list disclosed on 11 November 2022.

5 Fig 2. Myocarditis mortality rate ratios (MMRRs) by age and Standardised mortality ratio (SMR).

6

7

8 **Tables**

9 Table 1. Characteristics of included death cases after receiving SARS-CoV-2 vaccine.


10 Table 2. Number of persons who received vaccine by dose and person-years of exposure by age.

11 Table 3. Population, cause of death and mortality rate in the reference population by age.

12 Table 4. Myocarditis mortality rate ratios (MMRRs) by age by dose of vaccination.

13


14



**Fig 1| Included death cases for analysis based on the list disclosed on 11 November 2022.**

1  
2  
3





**Fig 2| Myocarditis mortality rate ratios(MMRRs) by age and Standardised mortality ratio (SMR).**

1

2

1

**Table 1| Characteristics of included death cases after receiving SARS-CoV-2 vaccine <sup>\*a</sup>**

	All-cause death N (%)	Myocarditis death N (%)
<b>Total</b>	1 374 (100.0)	32 (100.0)
<b>Age (years)</b>		
12-19	7 (0.5)	0 (0.0)
20-29	31 (0.3)	3 (3.3)
30-39	33 (1.5)	6 (6.6)
40-49	54 (0.9)	3 (3.3)
50-59	91 (2.8)	0 (0.0)
60-69	124 (2.2)	3 (3.3)
70-79	302 (0.0)	6 (6.6)
80-89	453 (5.3)	7 (7.7)
≥ 90	265 (2.4)	2 (2.2)
Unknown	2 (0.1)	0 (0.0)
<b>Sex</b>		
Male	750 (5.9)	21 (65.6)
Female	607 (6.6)	11 (34.4)
Unknown	5 (1.4)	0 (0.0)
<b>Vaccine type</b>		
BNT162b2 (Pfizer-BioNTech)	1 298 (11.3)	26 (81.3)
mRNA-1273 (Moderna)	63 (1.7)	6 (18.8)
ChAdOx1 nCoV-19 (Astra Zeneca)	1 (0.1)	0 (0.0)
<b>Number of doses of vaccination</b>		
1	753 (5.2)	13 (40.6)
2	556 (7.0)	18 (56.3)
Unknown <sup>*b</sup>	53 (0.9)	1 (3.1)

\*a: Onset of symptoms leading to death occurred within 28 days after receiving the last dose of vaccine.

\*b: Dose was surely first or second but not known which dose.

\*c: Diagnostic basis for the lower number does not include the diagnostic basis for the higher number.

\*d: Possibility could not be ruled out that "Other blood tests" include elevated troponin.

2

3

1

**Table 1(continued)| Characteristics of included death cases after receiving SARS-CoV-2 vaccine <sup>\*a</sup>**

	All-cause death N (%)	Myocarditis death N (%)
<b>Time from vaccination to onset of symptom</b>		
0 to 7 days	979 (11.1)	16 (50.0)
8 to 14 days	213 (1.6)	7 (21.9)
15 to 28 days	170 (0.4)	9 (28.1)
<b>Diagnostic basis for myocarditis deaths <sup>*c</sup></b>		
1.Autopsy and /or myocardial biopsy		16 (50.0)
2.Elevated Troponin with blood test		3 (9.4)
3.Other blood test <sup>*d</sup> and/or (ECG and/or UCG)		10 (31.3)
4.Only symptoms		1 (3.1)
5.Unknown		2 (6.3)

\*a: Onset of symptoms leading to death occurred within 28 days after receiving the last dose of vaccine.

\*b: Dose was surely first or second but not known which dose.

\*c: Diagnostic basis for the lower number does not include the diagnostic basis for the higher number.

\*d: Possibility could not be ruled out that "Other blood tests" include elevated troponin.

2

3

1

**Table 2| Number of persons who received vaccine by dose and person-years of exposure by age.**

Age (years)	Number of persons who received			Person-years		
	A. First dose, N	B. Only first dose, N	C. Second dose, N	D. First dose, N	E. Second dose, N	F. Total N (%)
12-19	6 881 439	147 798	6 733 641	419 700	516 553	936 253 (6.8)
20-29	10 272 284	141 353	10 130 931	625 234	777 167	1 402 401 (10.3)
30-39	11 526 243	120 385	11 405 858	700 943	874 970	1 575 913 (11.5)
40-49	15 392 743	99 856	15 292 887	935 098	1 173 153	2 108 250 (15.4)
50-59	15 331 940	65 721	15 266 219	930 862	1 171 107	2 101 969 (15.4)
60-69	13 926 130	38 967	13 887 163	845 176	1 065 317	1 910 493 (14.0)
70-79	15 300 344	43 875	15 256 469	928 595	1 170 359	2 098 954 (15.4)
80-89	8 875 050	41 716	8 833 334	538 898	677 626	1 216 523 (8.9)
≥ 90	2 328 370	17 729	2 310 641	141 489	177 255	318 744 (2.3)
Total	99 834 543	717 400	99 117 143	6 065 995	7 603 507	13 669 500 (100)

D=( A×22.14 + B×5.86 )/365 where 22.14 was the weighted average days from first dose to second dose and 5.86 is 28 days of observation period - 22.12. E=C×28/365

2

**Table 3 | Population, cause of death and mortality rate in the reference population by age.**

Age (years)	Population <sup>a</sup>	Number of deaths by cause <sup>a</sup>		Crude mortality rate (/100,000)	
	(2017~2019)	All-cause	Myocarditis	All-cause	Myocarditis
	N (%)	N (%)	N (%)		
10-19	33 897 000 (9.7)	4 807 (0.1)	16 (3.5)	14	0.05
20-29	37 697 000 (10.8)	12 621 (0.3)	20 (4.3)	33	0.05
30-39	43 927 000 (12.6)	23 183 (0.6)	25 (5.4)	53	0.06
40-49	56 179 000 (16.1)	67 014 (1.6)	48 (10.4)	119	0.09
50-59	48 037 000 (13.8)	140 399 (1.6)	54 (11.7)	292	0.11
60-69	50 918 000 (14.6)	388 709 (3.4)	92 (19.9)	763	0.18
70-79	45 582 000 (13.1)	819 510 (9.5)	101 (21.8)	1 798	0.22
80-89	26 491 000 (7.6)	1 499 479 (20.1)	84 (18.1)	5 660	0.32
≥ 90	6 545 000 (1.9)	1 118 796 (36.8)	23 (5.0)	17 094	0.35
Total	349 273 000 (100)	4 074 518 (100)	463 (100)	1 167	0.13

<sup>a</sup>a: Population and number of deaths were all total of 3 years

3

4

1

2

**Table 4| Myocarditis mortality rate ratios (MMRRs) by age by dose of vaccination.**

Age (years)	First dose					Second dose					Overall				
	Ob	Ex	MMRR	LL	UL	Ob	Ex	MMRR	LL	UL	Ob	Ex	MMRR	LL	UL
12-19	0	0.20	0.00	0.00	20.94	0	0.24	0.00	0.00	17.02	0	0.44	0.00	0.00	9.39
20-29	2	0.33	6.03	0.68	24.82	1	0.41	2.43	0.06	15.16	3	0.74	4.03	0.77	13.60
30-39	1	0.40	2.51	0.06	15.31	6	0.50	12.05	4.04	30.09	7	0.90	7.80	2.85	18.56
40-49	1	0.80	1.25	0.03	7.31	1	1.00	1.00	0.02	5.83	3	1.80	1.67	0.33	5.17
50-59	1	1.05	0.96	0.02	5.56	0	1.32	0.00	0.00	2.90	1	2.36	0.42	0.01	2.46
60-69	2	1.53	1.31	0.16	4.87	1	1.92	0.52	0.01	2.97	3	3.45	0.87	0.18	2.62
70-79	4	2.06	1.94	0.52	5.13	2	2.59	0.77	0.09	2.86	6	4.65	1.29	0.46	2.91
80-89	1	1.71	0.59	0.01	3.35	6	2.15	2.79	1.00	6.34	7	3.86	1.81	0.71	3.91
≥ 90	1	0.50	2.01	0.05	12.39	1	0.62	1.61	0.04	9.89	2	1.12	1.79	0.20	7.23
Crude	13	8.04	1.62	0.85	2.79	18	10.08	1.79	1.05	2.85	32	18.12	1.77	1.19	2.53
SMR			1.53	0.88	2.66			1.72	1.07	2.76			1.69	1.18	2.42

Abbreviations

Observed: Ob, Expected: Ex, Lower limit of 95% confidence interval: LL,

Upper limit of 95% confidence interval: UL,

Myocarditis mortality rate ratio: MMRR, Standardized mortality ratio: SMR.

3

4